Search results
Results from the WOW.Com Content Network
Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). They are found in raw plants/herbs such as cinnamon and bacteria (containing the inhibitor acarbose ).
ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products. [1] [2] [3] Subgroup A10 is part of the anatomical group A Alimentary tract and ...
Generally, drugs outlined within the ATC code A10 should be included in this category. Please see WP:PHARM:CAT for more information. Wikimedia Commons has media related to Anti-diabetic drugs .
Alpha-glucosidase inhibitors are a class of diabetes drugs found in plants/herbs like cinnamon; [3] however, they are technically not hypoglycemic agents because they do not have a direct effect on insulin secretion or sensitivity. These agents slow the digestion of starch in the small intestine, such that glucose from the starch enters the ...
Hence, α-glucosidase inhibitors (like acarbose) are used as anti-diabetic drugs in combination with other anti-diabetic drugs. Luteolin has been found to be a strong inhibitor of α-glucosidase. The compound can inhibit the enzyme up to 36% with a concentration of 0.5 mg/ml. [ 21 ] As of 2016, this substance is being tested in rats, mice and ...
Miglitol is an oral alpha-glucosidase inhibitor used in the treatment of type 2 diabetes.It works by reversibly inhibiting alpha-glucosidase enzymes in the small intestine, which delays the digestion of complex carbohydrates and subsequently reduces postprandial glucose levels. [1]
No such effect was seen with another drug of this class, nateglinide. [ 3 ] A 2020 Cochrane systematic review did not find enough evidence of reduction of all-cause mortality, serious adverse events, cardiovascular mortality, non-fatal myocardial infarction , non-fatal stroke or end-stage renal disease when comparing metformin monotherapy to ...
To change this template's initial visibility, the |state= parameter may be used: {{Oral hypoglycemics and insulin analogs | state = collapsed}} will show the template collapsed, i.e. hidden apart from its title bar. {{Oral hypoglycemics and insulin analogs | state = expanded}} will show the template expanded, i.e. fully visible.